최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.28 no.1, 2018년, pp.57 - 64
김혜린 (삼육대학교 약학대학)
Background: Patients experience significant differences in aspects of mortality, quality of life, and costs between during the year of receiving liver transplant (LT) and the subsequent years (post-LT). This study aimed to estimate the medical utilization and cost of LT for patients compared to post...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
간이식 어떤 상황에서 행해지는 치료법인가? | 간이식은 급성 또는 만성 간질환에 의해 간기능 저하가 심각하고, 간이식 이외 다른 치료에 반응하지 않은 경우 행해지는 치료법이다. 바이러스간염(B형 또는 C형간염)에 의한 진행성 간경변증, 만성적인 알코올 섭취, 만성 간질환에서 발생한 간세포암종, 소아에서 선천성·대사성 질환 등과 같은 다양한 원인질환에 의한 급만성 간부전이 간이식의 대상이 된다. | |
우리나라에서 수행된 간이식 비용연구를 연구한 결과 LT환자군과 Post-LT 환자군 간 차이가 큰 항목은 무엇이며, 어떤 특성때문에 차이가 발생하는 것으로 볼 수 있는가? | Post-LT 환자군에서는 주사료 6,835,867±4,404,305원, 투약·처방전료 3,491,785±2,796,192원, 입원료 1,445,682±2,508,431원, 수술·처치료 1,330,572±4,181,424원, 검사료 1,131,484±1,718,403원 순으로 높았고, 다음으로는 영상진단·방사선치료료, 진찰료 순이었다. LT 환자군과 Post-LT 환자군 간 차이가 큰 항목으로는 주사료 29,146,650±7,159,750원, 수술·처치료 26,915,049±6,122,371원, 검사료 10,999,402±2,563,091원으로 나타났는데(각각 p<0.0001), 이는 간이식술이 이루어지는 시기에 발생하는 비용의 특성을 반영하는 것으로 볼 수 있다. | |
간이식의 대상이 되는 질병들은 무엇인가? | 간이식은 급성 또는 만성 간질환에 의해 간기능 저하가 심각하고, 간이식 이외 다른 치료에 반응하지 않은 경우 행해지는 치료법이다. 바이러스간염(B형 또는 C형간염)에 의한 진행성 간경변증, 만성적인 알코올 섭취, 만성 간질환에서 발생한 간세포암종, 소아에서 선천성·대사성 질환 등과 같은 다양한 원인질환에 의한 급만성 간부전이 간이식의 대상이 된다.1) 국내 한 상급종합병원의 간이식 1000례 자료에 의하면, 바이러스간염과 간암이 간이식 원인질환의 90%를 차지하는 것으로 나타났다. |
The Korean Association for the Study of the Liver. White Paper on Liver Diseases in Korea. 2013. Available from http://www.kasl.org/bbs/index.html?codeency&category&gubun&idx&page1&number55&modeview&order&sort&keyfield&key. Accessed January 16, 2018.
Kim MS. Modification of Emergency Status in Deceased Donor Liver Allocation: Evidence for Korean Model of End-stage Liver Disease (MELD) System. J Korean Soc Transplant 2016; 30(2):51-8.
Lim Y-S. Acute liver failure in Korea: etiology, prognosis and treatment. Korean J Hepatol 2010; 16(1):5-18.
Lee HJ. Liver Transplantation in Liver Cirrhosis. CMH 2006;12(20): 85-9.
Korean Network for Organ Sharing. Guidance on organ transplant management in 2016. Available from https://www.konos.go.kr/konosis/common/bizlogic.jsp. Accessed January 16, 2018.
Korean Network for Organ Sharing. Statistics of Organ Transplantation Cases. Available from https://www.konos.go.kr/konosis/sub4/sub-04_03_01_pop.jsp. Accessed January 16, 2018.
The Korean Association for the Study of the Liver. Clinical Guideline for liver Cirrhosis: Ascites and other complications. 2017. Available from http://www.kasl.org/bbs/index.html?codeguide&cate-gory&gubun&idx&page1&number3358&modeview &order&sort&keyfield&key. Accessed on January 16, 2018.
Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/home.do. Accessed January 16, 2018.
Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162(6):397-406.
Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015; 22(11):882-9.
Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83.
Liu S, Watcha D, Holodniy M, et al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161(8):546-53.
Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162(6):407-19.
Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705.
Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One 2015;10(5):e0126984.
Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40(6):657-75.
Ke W, Zhang C, Liu L, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int 2016;10(6):924-36.
Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13(5):592-600.
Zhang C, Ke W, Gao Y, et al. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 2015;35(3):197-209.
San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2015;64(8):1277-88.
Samsung Medical Center-Organ transplantation Center. FAQ-Cost for organ transplantation. Available from http://www.samsunghospital.com/dept/main/index.do?DP_CODEOTC&MENU_ID 007085160. Accessed January 16, 2018.
Asan Medical Center-Organ Transplantation Center. Organ transplant procedure. Available from http://organ.amc.seoul.kr/asan/depts/organ/K/content.do?menuId1610. Accessed January 16, 2018.
Cruz RJ, Ranganathan S, Mazariegos G, et al. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013; 153(2):150-9.
Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232(4):490-500.
Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11(3):527-38.
Sakata H, Tamura S, Sugawara Y, et al. Cost analysis of adult-adult living donor liver transplantation in Tokyo University Hospital. J Hepatobiliary Pancreat Sci 2011;18(2):184-9.
Serper M, Bittermann T, Rossi M, et al. Functional status, healthcare utilization, and the costs of liver transplantation. Am J Transplant 2017. doi: 10.1111/ajt.14576. [Epub ahead of print]
Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Value in Health Regional Issues 2014;3:12-18.
Kitazawa T, Matsumoto K, Fujita S, et al. Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database. Transplant Proc 2017;49(1):4-9.
Lee H, Shin U, Lee C, et al. Medical Price Levels of OECD Countries: A Comparative Study: KMA Research Institute for Healthcare Policy, 2013. Available from http://www.dbpia.co.kr/Journal/ArticleDetail/NODE02467445. Accessed January 16, 2018.
Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3):340-8.
Kim Y, Shin S, Park J, et al. Costing methods in Healthcare: NECA, 2013. Available from https://www.neca.re.kr/lay1/bbs/S1T11C102/F/39/view.do?article_seq5332&cpage1&rows10&condition&keyword&show&cat. Accessed January 16, 2018.
Kim H-L, Park J-A, Sin J, et al. Analysis of Medical Use and Costs Related to the Management of Liver Cirrhosis Using National Patients Sample Data. Korean J Clin Pharm 2016;26(4):341-7.
Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1):18-27.
Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One 2016; 11(6): e0155934.
Chhatwal J, He T, Hur C, et al. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving. Clin Gastroenterol Hepatol 2016;15(6):827-37.
Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016:1-14.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.